Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)

A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.

Study Overview

• Status: Recruiting
• Conditions: Biliary Tract Cancer
• Intervention / Treatment: Biological: Durvalumab; Drug: Gemcitabine monotherapy; Drug: Gemcitabine + cisplatin; Drug: Gemcitabine + oxaliplatin; Drug: Gemcitabine + carboplatin; Drug: Gemcitabine + cisplatin + S-1; Drug: Gemcitabine + S-1; Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel

Detailed Description

This study involves assessing the safety and efficacy of durvalumab in combination with different gemcitabine-based chemotherapy regimens as first line therapy for aBTC. The target population of interest in this study is participants with aBTC who are ≥ 18 years of age and above legal age per local regulations with WHO/ECOG PS of 0 to 2 at enrolment and who are not eligible for locoregional therapy. Participants with WHO/ECOG PS 2 will be capped at 20% of the overall treated participant population.

The study consists of 4 periods: screening period (Day-28 to Day -1), treatment period up to 8 cycles of gemcitabine-based chemotherapy regimens with durvalumab, maintenance treatment with durvalumab alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), and then safety and survival follow-up.

• Study Type: Interventional
• Enrollment (Estimated): 140
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: AstraZeneca Clinical Study Information Center; Phone Number: 1-877-240-9479; Email: information.center@astrazeneca.com

Study Locations

• France
  • Clichy, France, 92110
    • Not yet recruiting
    • Research Site
  • Dijon, France, 21079
    • Not yet recruiting
    • Research Site
  • Lyon Cedex 03, France, 69437
    • Not yet recruiting
    • Research Site
  • Montpellier Cedex 5, France, 34090
    • Not yet recruiting
    • Research Site
  • Pessac, France, 33604
    • Not yet recruiting
    • Research Site
  • Rennes, France, 35042
    • Not yet recruiting
    • Research Site
  • Villejuif, France, 94800
    • Not yet recruiting
    • Research Site
• Germany
  • Chemnitz, Germany, 09131
    • Not yet recruiting
    • Research Site
  • Freudenstadt, Germany, 72250
    • Withdrawn
    • Research Site
  • Hannover, Germany, 30625
    • Not yet recruiting
    • Research Site
  • Muenchen, Germany, 81377
    • Not yet recruiting
    • Research Site
• Italy
  • Castelfranco Veneto, Italy, 31033
    • Not yet recruiting
    • Research Site
  • Foggia, Italy, 71122
    • Not yet recruiting
    • Research Site
  • Palermo, Italy, 90146
    • Not yet recruiting
    • Research Site
  • Pisa, Italy, 56126
    • Not yet recruiting
    • Research Site
  • Rozzano, Italy, 20089
    • Not yet recruiting
    • Research Site
• Japan
  • Chuo-ku, Japan, 104-0045
    • Recruiting
    • Research Site
  • Kanazawa-shi, Japan, 920-8641
    • Recruiting
    • Research Site
  • Kashiwa, Japan, 227-8577
    • Recruiting
    • Research Site
  • Kyoto, Japan, 606-8507
    • Recruiting
    • Research Site
  • Osaka, Japan, 541-8567
    • Recruiting
    • Research Site
  • Sendai, Japan, 980-8574
    • Recruiting
    • Research Site
  • Ube, Japan, 755-8505
    • Recruiting
    • Research Site
  • Wakayama, Japan, 641-8509
    • Recruiting
    • Research Site
  • Yokohama, Japan, 241-8515
    • Recruiting
    • Research Site
• Korea, Republic of
  • Seoul, Korea, Republic of, 05505
    • Recruiting
    • Research Site
  • Seoul, Korea, Republic of, 06351
    • Recruiting
    • Research Site
  • Seoul, Korea, Republic of, 03080
    • Recruiting
    • Research Site
• Singapore
  • Singapore, Singapore, 169610
    • Recruiting
    • Research Site
  • Singapore, Singapore, 258499
    • Suspended
    • Research Site
  • Singapore, Singapore, 329563
    • Suspended
    • Research Site
• Spain
  • Barcelona, Spain, 08035
    • Not yet recruiting
    • Research Site
  • Barcelona, Spain, 08036
    • Not yet recruiting
    • Research Site
  • Madrid, Spain, 28027
    • Not yet recruiting
    • Research Site
  • Madrid, Spain, 28040
    • Not yet recruiting
    • Research Site
  • Madrid, Spain, 28007
    • Not yet recruiting
    • Research Site
  • Madrid, Spain, 28041
    • Not yet recruiting
    • Research Site
  • Pamplona, Spain, 31008
    • Not yet recruiting
    • Research Site
  • Sevilla, Spain, 41013
    • Not yet recruiting
    • Research Site
• United States
  • Alabama
    • Mobile, Alabama, United States, 36607
      • Not yet recruiting
      • Research Site
  • California
    • Orange, California, United States, 92868
      • Recruiting
      • Research Site
  • District of Columbia
    • Washington, District of Columbia, United States, 20010
      • Not yet recruiting
      • Research Site
    • Washington, District of Columbia, United States, 20007
      • Recruiting
      • Research Site
  • New York
    • New York, New York, United States, 10029
      • Withdrawn
      • Research Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73142
      • Recruiting
      • Research Site
  • Oregon
    • Portland, Oregon, United States, 97213
      • Recruiting
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 130 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Histologically confirmed, unresectable advanced or metastatic biliary tract carcinoma (BTC) including cholangiocarcinoma (intrahepatic or extrahepatic), gallbladder carcinoma, and ampulla of Vater (AoV) carcinoma
• Participants with unresectable or metastatic BTC
• A World Health Organisation Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) of 0 to 2
• At least one lesion that qualifies as a Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) target lesion at baseline
• Adequate organ and bone marrow function
• Body weight of > 30 kg
• Negative pregnancy test (serum) for women of childbearing potential
• Female participants must be one year post-menopausal (amenorrhoeic for 12 months without an alternative medical cause)
• Male and female participants and their partners must be surgically sterile or on their chosen method of birth control as per the protocol.

Exclusion Criteria:

• Any evidence of diseases such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diseases, active infection, active interstitial lung disease/pneumonitis, serious chronic gastrointestinal conditions associated with diarrhoea, psychiatric illness/social situations, history of uncontrolled or symptomatic cardiac disease, and history of allogenic organ transplant
• Active or prior documented autoimmune or inflammatory disorders
• History of another primary malignancy, except for malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study intervention
• History of leptomeningeal carcinomatosis
• History of active primary immunodeficiency
• Known to have tested positive for human immunodeficiency virus [HIV] (positive HIV 1/2 antibodies) or active tuberculosis infection
• Participants co-infected with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) or co-infected with HBV and Hepatitis D virus (HDV)
• Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade > 1) caused by previous anticancer therapy
• Central nervous system metastases requiring treatment or history of spinal cord compression
• Known allergy or hypersensitivity to any of the study intervention or any of the study intervention excipients.
• Any concurrent chemotherapy, other than the one allowed in the study, investigational medicinal product (IMP), biologic, or hormonal therapy for cancer treatment
• Palliative radiotherapy with a limited field of radiation within 2 weeks of the first dose of study intervention, or radiotherapy with a wide field of radiation or radiotherapy affecting more than 30% of the bone marrow within 4 weeks before the first dose of study intervention
• Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention
• Major surgical procedure within 28 days prior to the first dose of IMP
• Prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines
• Receipt of the last dose of anticancer therapy within 28 days prior to the first dose of IMP

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Durvalumab + Gemcitabine based chemotherapy; Participants will receive durvalumab 1500mg every 3 or 4 weeks, in combination with continuation of all or some of the original background gemcitabine based chemotherapy every 3 or 2 weeks for up to a maximum of 8 cycles of chemotherapy. Durvalumab 1500mg is given as a 60-minute IV infusion in the first cycle (Day 1) and as a 30-minute IV infusion in following cycles. Upon completing 8 cycles of background gemcitabine-chemotherapy, or after discontinuing any of the combination chemotherapies due to toxicity before completing 8 cycles, participants are eligible to continue receiving durvalumab 1500 mg IV every 4 weeks either alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), as per investigator's discretion.

Biological: Durvalumab; Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy); Other Names: Background Gemcitabine-based Chemotherapy Regimen; Drug: Gemcitabine monotherapy; Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab); Other Names: Background Gemcitabine-based Chemotherapy Regimen; Drug: Gemcitabine + cisplatin; Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only; Other Names: Background Gemcitabine-based Chemotherapy Regimen; Drug: Gemcitabine + oxaliplatin; Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab); Other Names: Background Gemcitabine-based Chemotherapy Regimen; Drug: Gemcitabine + carboplatin; Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab); Other Names: Background Gemcitabine-based Chemotherapy Regimen; Drug: Gemcitabine + cisplatin + S-1; Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab); Other Names: Background Gemcitabine-based Chemotherapy Regimen.; This regimen is not allowed for countries in the European Union.; Drug: Gemcitabine + S-1; Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab); Other Names: Background Gemcitabine-based Chemotherapy Regimen; This regimen is not allowed for countries in the European Union.; Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel; Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab); Other Names: Background gemcitabine-based chemotherapy Regimen; This regimen is not allowed for countries in the European Union.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with Grade 3 or 4 possibly related adverse event (PRAE)	PRAE is defined as an AE which has been assessed by the investigator to be possibly related to IMP.	Within 6 months after the initiation of Investigational Medicinal Product (IMP)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	OS is defined as the time from the date of the first dose of IMP until death due to any cause.	From the date of the first dose of IMP until death due to any cause [approx. upto 33 months]
Objective Response Rate (ORR)	ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1.	From the date of first dose of IMP until progression, or the last evaluable assessment in the absence of progression [assessed up to 33 months]
Progression-Free Survival (PFS)	PFS is defined as the time from the first dose of IMP until the date of disease progression (PD) or death due to any cause.	From the date of the first dose of IMP until until the date of objective PD or death [approx. up to 33 months]
Disease Control Rate (DCR)	DCR is defined as the % of participants who have a best objective response of complete response or partial response (by week 24 or 32), or who have stable disease for 24 or 32 weeks.	Week 24 and Week 32
Duration of Response (DOR)	DOR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression.	From the date of first documented response until the first date of documented progression or death in the absence of disease progression [approx. up to 33 months]
Duration of Treatment (DOT)	DOT is defined as time on study intervention.	From date of start of IMP, until 27 days after last dose of IMP or date of death [approx. up to 33 months]
Number of participants with AEs, including PRAEs, adverse events of special interest (AESIs), immune-mediated adverse events (imAEs) and serious adverse events (SAEs)	To assess the safety and tolerability profile of durvalumab combined with background gemcitabine-based chemotherapy	From the date of first dose of IMP until long-term follow-up i.e. until 90 days following discontinuation of the last dose of IMP [approx. up to 33 months]
Number of participants with IRRs and hypersensitivity/anaphylactic reactions	To assess the safety and tolerability profile of durvalumab combined with background gemcitabine-based chemotherapy	From the date of first dose of IMP until 90 days following discontinuation of the last dose of IMP [approx. up to 33 months]
European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ C-30)	To assess disease and treatment related symptoms and HRQoL. EORTC QLQ-C30 consists of 30 items and measures symptoms, functioning, and global health status/QoL for all cancer types. Questions are grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer participants (dyspnoea, loss of appetite, insomnia, constipation, and diarrhoea), and one item on the financial impact of the disease. The EORTC QLQ-C30 is a valid and reliable PRO instrument in this participant population	From date of first dose of IMP, until the date of the first clinically meaningful deterioration [approx. up to 33 months]
EORTC QLQ-BIL21 Score	To assess disease- and treatment related symptoms and HRQoL. The EORTC QLQ-BIL21 is a disease-specific (cholangiocarcinoma and cancer of the gallbladder) questionnaire. It consists of 21 items including one question each for side effects, equipment issues, and weight loss, as well as 5 scales (eating symptoms, jaundice symptoms, tiredness, pain, and anxiety). A higher score indicates greater difficulties. The EORTC QLQ-BIL21 is a valid and reliable PRO instrument in this participant population.	From date of first dose of IMP, until the date of the first clinically meaningful deterioration [approx. up to 33 months]

Collaborators and Investigators

• Sponsor: AstraZeneca

Study record dates

Study Major Dates

• Study Start (Actual): August 16, 2023
• Primary Completion (Estimated): September 17, 2025
• Study Completion (Estimated): March 17, 2026

Study Registration Dates

• First Submitted: March 6, 2023
• First Submitted That Met QC Criteria: March 6, 2023
• First Posted (Actual): March 16, 2023

Study Record Updates

• Last Update Posted (Actual): April 12, 2024
• Last Update Submitted That Met QC Criteria: April 11, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: monoclonal antibodies; Durvalumab; PD-L1 antagonist
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Digestive System Neoplasms; Biliary Tract Diseases; Biliary Tract Neoplasms; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Antineoplastic Agents, Immunological; Carboplatin; Paclitaxel; Cisplatin; Oxaliplatin; Durvalumab; Albumin-Bound Paclitaxel; Gemcitabine
• Other Study ID Numbers: D4191C00140; 2022-002527-35 (EudraCT Number); 2022-502043-35 (Registry Identifier: CTIS (EU))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No